CAR T-Cell Therapy for Advanced Prostate Cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed prostate cancer diagnosis that has spread to other parts of the body and is resistant to hormone therapy
- PSA level of 4 or higher at screening, with cancer that has grown within the last 6 months
- Previously received at least 2 approved cancer treatments for advanced prostate cancer, including at least one modern hormone therapy (such as abiraterone, enzalutamide, apalutamide, or darolutamide)
- Currently on castration therapy (either surgical removal of testicles or ongoing hormone injections) with testosterone levels below 50 ng/dL
- Adequate kidney, liver, and bone marrow function based on blood tests
- No active blood clots or unstable bone fractures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy called A-CAR032, which uses your own immune cells to attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
This Phase 1 study tests a type of immune cell treatment (CAR T) made to recognize PSMA, a marker on prostate cancer cells. It’s for advanced prostate cancer and aims to find a safe dose and how well the treatment works.
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
This trial tests a new immune cell therapy, called STEAP1 IL-18 CAR T cells, for men with advanced prostate cancer that has stopped responding to standard treatments. The therapy is designed to help your immune system fight the cancer more effectively.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.